Combined analysis of retrospective and prospective studies to evaluate the significance of FCα receptor polymorphisms in response to cetuximab plus irinotecan therapy for chemorefractory Japanese patients with advanced and/or metastatic colorectal cancer.
Hideki Shimodaira
No relevant relationships to disclose
Hiroshi Soeda
No relevant relationships to disclose
Keigo Komine
No relevant relationships to disclose
Masahiro Inoue
No relevant relationships to disclose
Masanobu Takahashi
No relevant relationships to disclose
Shin Takahashi
No relevant relationships to disclose
Mika Watanabe
No relevant relationships to disclose
Shunsuke Kato
No relevant relationships to disclose
Makio Gamoh
No relevant relationships to disclose
Chikashi Ishioka
Research Funding - Chugai Pharma; Taiho Pharmaceutical